Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16653| Title: | Altered levels of blood proteins in Alzheimer's disease longitudinal study: results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort | Austin Authors: | Gupta, Veer Bala;Hone, Eugene;Pedrini, Steve;Doecke, James;O'Bryant, Sid;James, Ian;Bush, Ashley I;Rowe, Christopher C ;Villemagne, Victor L ;Ames, David;Masters, Colin L ;Martins, Ralph N;AIBL Research Group | Affiliation: | Austin Health, Heidelberg, Victoria, Australia School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia Co-operative Research Centre for Mental Health, Carlton, Victoria, Australia CSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Queensland, Australia Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA School of Engineering and Information Technology, Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia National Ageing Research Institute, Parkville, Victoria, Australia Academic Unit for Psychiatry of Old age, St. George's Hospital, The University of Melbourne, Melbourne, Victoria, Australia School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, Australia |
Issue Date: | 23-Apr-2017 | Date: | 2017-04-23 | Publication information: | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017; 8: 60-72 | Abstract: | INTRODUCTION: A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. METHODS: We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. RESULTS: Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P = .0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P = .0008). DISCUSSION: These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16653 | DOI: | 10.1016/j.dadm.2017.04.003 | ORCID: | 0000-0003-3910-2453 | Journal: | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/28508031 | Type: | Journal Article | Subjects: | Alzheimer's disease Biomarkers Blood |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.